Immunogenicity of a BNT162b2 vaccine booster in health-care workers

QR Code

Immunogenicity of a BNT162b2 vaccine booster in health-care workers

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Esther Saiag, Hanoch Goldshmidt, Eli Sprecher, Ronen Ben-Ami, David Bomze
Format:	article
Langue:	EN
Publié:	Elsevier 2021
Sujets:	Medicine (General) R5-920 Microbiology QR1-502
Accès en ligne:	https://doaj.org/article/e53c202b413f422980d0e01d97a9c7d8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
par: Serge Goldman, et autres
Publié: (2021)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
par: Mohammad Shehab, et autres
Publié: (2021)

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers – a single centre cohort study
par: Tariq Azamgarhi, et autres
Publié: (2021)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
par: Nicola Silvestris
Publié: (2021)

Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS
par: Domenico Pascucci, et autres
Publié: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
par: Timothy A. Bates, et autres
Publié: (2021)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
par: Yamato Nishiguchi, et autres
Publié: (2021)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
par: Chiara Agrati, et autres
Publié: (2021)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
par: Elvira Baos, et autres
Publié: (2022)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
par: Akihiro Matsubara, et autres
Publié: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
par: Toshiyuki Sumi, et autres
Publié: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
par: Krzysztof Lukaszuk, et autres
Publié: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
par: Benjamin Kahn, BA, et autres
Publié: (2021)

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
par: Dafna Yahav, et autres
Publié: (2021)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
par: Rana Shibli, et autres
Publié: (2021)

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
par: Michael Cross, et autres
Publié: (2021)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
par: Jia Ming Low, et autres
Publié: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
par: Jing Zou, et autres
Publié: (2021)

B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
par: Federica Pulvirenti, et autres
Publié: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
par: Delphina Gomes, et autres
Publié: (2021)

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine
par: Mira FS, et autres
Publié: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
par: Davide Ferrari, et autres
Publié: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
par: Delphina Gomes, et autres
Publié: (2021)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
par: Shai Efrati, et autres
Publié: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
par: Kazuki Takada, MD, PhD, et autres
Publié: (2021)

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
par: Hamad Ali, et autres
Publié: (2021)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
par: Ilaria Vicenti, et autres
Publié: (2021)

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers
par: Khalid Alhasan, et autres
Publié: (2021)

COVID-19 Vaccine Hesitancy and Attitude toward Booster Doses among US Healthcare Workers
par: Suman Pal, et autres
Publié: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
par: Kenji Maeda, et autres
Publié: (2021)

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
par: Julie Demaret, et autres
Publié: (2021)

THE EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF THE POLYSACCHARIDE PNEUMOCOCCAL VACCINE DURING THE IMMUNIZATION OF HEALTH CARE WORKERS
par: I. V. Feldblum, et autres
Publié: (2014)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
par: Doris Urlaub, et autres
Publié: (2021)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
par: M.D. Maldonado, et autres
Publié: (2021)

COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
par: Piotr Rzymski, et autres
Publié: (2021)

Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran
par: Farhang Babamahmoodi, et autres
Publié: (2021)

Possible HSP reactivation post‐COVID‐19 vaccination and booster
par: Makoto Kondo, et autres
Publié: (2021)

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
par: Piotr Rzymski, et autres
Publié: (2021)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
par: Chin-Shern Lau, et autres
Publié: (2021)

Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
par: Matteo Nioi, et autres
Publié: (2021)